ESMO Conference Coverage
Filter News By:
Featured News
View all
More News
(Evaluate Vantage) Sept 23, 2020 - The company’s EGFR and cMet targeted bispecific has generated early but encouraging signals in lung cancer – however, J&J faces stiff competition.
(MedPage Today) Sept 23, 2020 - An immunotherapy boost failed to improve outcomes in newly diagnosed advanced ovarian cancer compared with chemotherapy and bevacizumab (Avastin), a large international trial showed.
(ESMO 2020) Sept 22, 2020 - No significant difference was observed in the risk of recurrence, local recurrence, or death between patients with cervical cancer in whom radical uterine procedure (mostly radical hysterectomy) was completed or...
(MedPage Today) Sept 21, 2020 - An investigational inhibitor of apoptosis proteins (IAPs) extended survival in locally advanced head and neck squamous cell carcinoma (SCC) when added to standard chemoradiotherapy, according to an updated...
(U.S. News & World Report/HealthDay News) Sept, 22, 2020 - People with cancer are at increased risk for severe COVID-19. Now, a preliminary study suggests that certain cancer therapies may heighten those odds even further.
(Merck) Sept 21, 2020 - KEYTRUDA plus chemotherapy demonstrated superior overall survival and progression-free survival versus chemotherapy in these patients regardless of PD-L1 expression status and tumor histology. Results from...
(BMS) Sept 21, 2020 - Overall survival and progression-free survival benefit observed in patients whose tumors express PD-L1; overall survival benefit also observed in all-randomized population. Efficacy benefit observed across patients...
(ESMO) Sept 21, 2020 - New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival.
(Medscape Medical News) Sept 21, 2020 - An international survey provides new insights into how COVID-19 has affected, and may continue to affect, the field of oncology.
(BMS) Sept 21, 2020 - Adjuvant Opdivo doubled disease-free survival; is the first therapeutic option to show statistically significant and clinically meaningful disease-free survival benefit in these patients, regardless of tumor...
Expert Videos

OBR Tweets

Sep 24
Cristina Suárez, MD, of @vallhebron offers opinion on whether the CheckMate 9ER trial is practice-changing #ESMO20 https://t.co/6m8UCjJPxE

Sep 24
Andrew Schmidt, MD, @dr_aschmidt of @DanaFarber regarding the COVID-19 and Cancer Outcomes Study (CCOS) presented a… https://t.co/tbmT0twPFA

Sep 24
Erika Hamilton, MD, @ErikaHamilton9 of @SarahCannonDocs regarding the Phase III monarchE trial presented at #ESMO20 https://t.co/AiqtvpEZ7u

Sep 24
Giuseppe Giaccone, PhD, MD, of @WeillCornell regarding the step 1 results of the Phase III ATALANTE-1 trial in NSCL… https://t.co/D5Su3qEkbb

Sep 24
Pasi A. Jänne, MD, PhD, of @DanaFarber shares data from #ESMO20 investigating mobocertinib https://t.co/idTloLVyBj

Sep 24
Maha Hussain, MD, of @LurieCancer provides perspective on the Phase III PROfound study presented at #ESMO20 https://t.co/NerWJUf67S

Aug 25
At the ASCO20 Virtual Education Program, Nilanjan Ghosh, MD, PhD, a hematologist-oncologist at the @LevineCancer, p… https://t.co/o2s69MGfrW

Aug 25
At the #ASCO20 Virtual Education Program, Jaleh Fallah @Jaleh_Fallah, MD, a Hematology/Oncology Fellow at the Cleve… https://t.co/QDkyebDuvp

Aug 25
The financial toxicity that patients and oncology practices are potentially exposed to due to the high costs associ… https://t.co/QA8A13PAGT

Aug 25
At separate #AACR and #COA virtual meetings held in July, participants discussed the challenges of providing cancer… https://t.co/8fs8SKl65a